Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls

Bone

Volumn 51, Issue 3, 2012, Pages 474-479

  Faje, Alexander T ^a   Fazeli, Pouneh K ^a   Katzman, Debra K ^b   Miller, Karen K ^a   Breggia, Anne ^c   Rosen, Clifford J ^c   Mendes, Nara ^a   Klibanski, Anne ^a   Misra, Madhusmita ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c Maine Medical Center Research Institute   (United States)

Author keywords

Anorexia nervosa; Osteoporosis; Sclerostin

Indexed keywords

CALCIUM; ESTRADIOL; MEDROXYPROGESTERONE; PLACEBO; SCLEROSTIN; VITAMIN D;

ADOLESCENT; ADULT; ANOREXIA NERVOSA; ARTICLE; BONE DENSITY; BONE TURNOVER; CANADA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; HORMONE ACTION; HUMAN; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ANOREXIA NERVOSA; BIOLOGICAL MARKERS; BODY COMPOSITION; BODY WEIGHT; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; CASE-CONTROL STUDIES; ESTRADIOL; FEMALE; GENETIC MARKERS; HEALTH; HORMONE REPLACEMENT THERAPY; HUMANS;

EID: 84864754276     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.06.006     Document Type: Article

References (36)

1. Van Bezooijen R.L., Papapoulos S.E., Lowik C.W.G.M. Bone morphogenetic protein and their antagonists: the sclerostin paradigm. J Endocrinol Invest 2005, 28:15-17.
2. Li X., Zhang Y., Kang H., Liu W., Liu P., Zhang J., et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005, 280:19883-19887.
3. Semenov M., Tamai K., He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 2005, 280:26770-26775.
4. Wijenayaka A.R., Kogawa M., Lim H.P., Bonewald L.F., Findlay D.M., Atkins G.J. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 2011, 6:e25900.
5. Balemans W., Ebeling M., Patel N., van Hul E., Olson P., Dioszegi M., et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001, 10:537-543.
6. Balemans W., Patel N., Ebeling M., van Hul E., Wuyts W., Lacza C., et al. Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002, 39:91-97.
7. Huang Q.Y., Li G.H.Y., Kung A.W.C. The -9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPalpha and FOXA1 binding is associated with osteoporosis. Bone 2009, 45:289-294.
8. Mirza F.S., Padhi I.D., Raisz L.G., Lorenzo J.A. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 2010, 95:1991-1997.
9. Modder U.I., Roforth M.M., Hoey K., McCready L.K., Peterson J.M., Monroe D.G., et al. Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. Bone 2011, 49:202-207.
10. Modder U.I., Clowes J.A., Hoey K., Peterson J.M., McCready L., Oursler M.J., et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res 2011, 26:27-34.
11. Chung Y.E., Lee S.H., Lee S.Y., Kim S.Y., Kim H.H., Mirza F.S., et al. Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos Int 2012, 231235-231243.
12. Soyka L., Misra M., Frenchman A., Miller K., Grinspoon S., Schoenfeld D., et al. Abnormal bone mineral accrual in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 2002, 87:4177-4185.
13. Bachrach L.K., Guido D., Katzman D., Litt I.F., Marcus R. Decreased bone density in adolescent girls with anorexia nervosa. Pediatrics 1990, 86:440-447.
14. Saggese G., Bertelloni S., Baroncelli G.I., Di Nero G. Serum levels of carboxyterminal propeptide of type 1 proco llagen in healthy children from 1st year of life to adulthood and in metabolic bone diseases. Eur J Pediatr 1992, 151:764-768.
15. Soyka L.A., Grinspoon S., Levitsky L.L., Herzog D.B., Klibanski A. The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab 1999, 84:4489-4496.
16. Fazeli P.K., Lawson E.A., Prabhakaran R., Miller K.K., Donoho D.A., Clemmons D.R., et al. Effects of recombinant human growth hormone in anorexia: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2010, 95:4889-4897.
17. Misra M., Miller K.K., Griffin K., Stewart V., Hunter E., Herzog D.B., et al. Secretory dynamics of leptin in adolescent girls with anorexia nervosa and healthy adolescents. Am J Physiol Endocrinol Metab 2005, 289:373-381.
18. Misra M., Miller K.K., Kuo K., Griffin K., Stewart V., Hunter E., et al. Secretory dynamics of ghrelin in adolescent girls with anorexia nervosa and healthy adolescents. Am J Physiol Endocrinol Metab 2005, 289:347-356.
19. Misra M., Miller K.K., Almazan C., Ramaswamy K., Lapcharoensap W., Worley M., et al. Alterations in cortisol secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J Clin Endocrinol Metab 2004, 89:4972-4980.
20. Misra M., Katzman D., Miller K.K., Mendes N., Snelgrove D., Russell M., et al. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Miner Res 2011, 26:2430-2438.
21. Greulich W., Pyle S. Radiographic atlas of skeletal development of the hand and wrist 1959, Stanford University Press, Stanford. 2nd ed.
22. Misra M., Tsai P., Anderson E.J., Hubbard J.L., Gallagher K., Soyka L.A., et al. Nutrient intake in community-dwelling adolescent girls with anorexia nervosa and in healthy adolescents. Am J Clin Nutr 2006, 84:698-706.
23. Kirmani S., Amin S., McCready L.K., Atkinson E.J., Melton L.J., Muller R., et al. Sclerostin levels during growth in children. Osteoporos Int 2012, 23:1123-1130.
24. Yu E.W., Kumbhani R., Siwila-Sackman E., Leder B.Z. Acute decline in serum sclerostin in response to PTH infusion in healthy Men. J Clin Endocrinol Metab 2011, 96:E1848-E1851.
25. Drake M.T., Srinivasan B., Modder U.I., Peterson J.M., McCready L.K., Riggs B.L., et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 2011, 95:5056-5062.
26. Ardawi M.S.M., Al-Sibiany A.M., Bakhsh T.M., Rouzi A.A., Qari M.H. Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study. Osteoporos Int 2012, 23:1789-1797.
27. van Lierop A.H., Witteveen J.E., Hamdy N.A.T., Papapoulos S.E. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol 2010, 163:833-837.
28. Costa A.G., Cremers S., Rubin M.R., McMahon D.J., Sliney J., Lazaretti-Castro M., et al. Circulating sclerostin in disorders of parathyroid gland function. J Clin Endocrinol Metab 2011, 96:3804-3810.
29. Kaji H., Imanishi Y., Sugimoto T., Seino S. Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism, and osteomalacia. Exp Clin Endocrinol Diabetes 2011, 119:440-444.
30. Keller H., Kneissel M. SOST is a target gene for PTH in bone. Bone 2005, 37:148-158.
31. Ardawi M.M., Al-Kadi H.A., Rouzi A.A., Qari M.H. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res 2011, 26:2812-2822.
32. Yao W., Cheng Z., Pham A., Busse C., Zimmermann E.A., Ritchie R.O., et al. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 2008, 58:3485-3497.
33. Pineda B., Hermenegildo C., Tarin J.J., Cano A., Garcia-Perez M.A. Effects of administration of hormone therapy or raloxifene on the immune system and on biochemical markers of bone remodeling. Menopause 2012, 19:319-327.
34. Christodoulides C., Laudes M., Cawthorn W.P., Schinner S., Soos M., O'Rahilly S., et al. The Wnt antagonist Dickkopf-1 and its receptors are coordinately regulated during early human adipogenesis. J Cell Sci 2006, 119:2613-2620.
35. McNulty M., Singh R.J., Li X., Bergstralh E.J., Kumar R. Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. J Clin Endocrinol Metab 2011, 96:E1159-E1162.
36. Veverka V., Henry A.J., Slocombe P.M., Ventom A., Mulloy B., Muskett F.W., et al. Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 2009, 284:10890-10900.